Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Emory researchers identify signaling protein for multiple myeloma

Emory researchers identify signaling protein for multiple myeloma

September 11, 2007

Findings may result in new therapeutic target

Researchers at Emory University's Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival. Their research may result in identification of a new therapeutic target for treating multiple myeloma.




The results of the study appear in the September issue of Cancer Cell. Jing Chen, PhD, assistant professor of hematology and oncology at Emory Winship and a Georgia Cancer Coalition Distinguished Cancer Scholar, is senior author on the paper. Sumin Kang, PhD, a postdoctoral fellow at Emory Winship, is the paper's first author.

Multiple Myeloma is among the most common hematologic malignancies in patients over 65. About15 percent of multiple myeloma patients harbor a genetic abnormality called "t(4;14) chromosomal translocation" that causes over-expression of a tyrosine kinase called fibroblast growth factor receptor 3 (FGFR3).

Tyrosine kinases are molecules that act as biological switches inside cells, regulating processes including cell division and growth. Abnormal kinases have been identified as a driving force in many forms of cancer.

"We are interested in how FGFR3 mediates transforming signals," says Dr. Chen. "We wanted to know which protein factors in cells are activated by FGFR3 and then transform normal cells to highly malignant cells. We identified Ribosomal S6 kinase 2 (RSK2), which is a protein factor that mediates signaling in cells as critical in downstream signaling of FGFR3 in myeloma cells."

Dr. Chen and his colleagues are the first to discover a mechanism to "turn-on" RSK2 by FGFR3. FGFR3 impacts downstream proteins through phosphorylation at special "tyrosine" sites.

"We found that FGFR3 directly phosphorylates RSK2, which is a critical step in the process to activate (turn-on) RSK2," says Dr. Chen.

The researchers observed that elimination of RSK2 proteins or shutting down RSK2 activity blocks FGFR3 transformation signaling in myeloma cells. This means FGFR3 requires RSK2 to transform normal cells.

"This is a beautiful model," says Dr. Chen. "We are able to mark the connection between the oncogenic FGFR3 and its downstream protein kinase RSK2, which plays a critical role in regulation of cell cycle and survival. These findings extend our understanding of pathogenesis of multiple myeloma in a signaling basis."

Collaborators on the project include Roberto Polakiewicz, PhD, and Ting-Lei Gu, PhD, both of Cell Signaling Technologies (CST), developers of the "PhosphoScan" technology, which enables investigators to identify hundreds to thousands of phosphorylated sequences and observe the global state of protein tyrosine phosphorylation in cells and tissues.

"Using this technology," says Dr. Chen, "we identified RSK2 as a critical downstream signaling protein effector of FGFR3 in myeloma cells." Other authors include researchers from the University of California at San Francisco, Harvard Medical School, Mayo Clinic and Novartis Pharma AG.

Dr. Chen and his colleagues also tested a drug called fmk that was designed by co-author Jack Taunton, PhD, at UCSF to specifically target RSK2 in treatment of human malignant myeloma cells from laboratory culture or primary samples from multiple myeloma patients, and saw that fmk effectively kills t(4;14) myeloma cells with abnormal over-expression of FGFR3.

"This study shows the potential utility of drugs that block the downstream effectors of mutant tyrosine kinases, and that these drugs are opening more doors to treating hematologic malignancies and cancers," explains Dr. Chen. In addition to the t(4;14) in multiple myeloma that is caused by abnormal over-expression of FGFR3, abnormality of FGFR3 has also been identified in human bladder and cervical cancers. The findings suggest, the authors write, that targeting RSK2 with RSK inhibitors such as fmk may be effective in treating t(4;14) multiple myeloma, as well as other diseases and cancers where mutant FGFR3 is the culprit.

Emory University



Related Multiple Myeloma Current Events and Multiple Myeloma News Articles Multiple Myeloma Current Events and Multiple Myeloma News RSS Multiple Myeloma Current Events and Multiple Myeloma News RSS
Cancers' Sweet Tooth May Be Weakness
The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.

Approved lymphoma drug shows promise in early tests against bone cancer
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.

Experimental drug lets B cells live and lymphoma cells die
An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

Boron-based compounds trick a biomedical protein
Chemists and biologists have successfully demonstrated that specially synthesized boron compounds are readily accepted in biologically active enzymes, a move that, they say, is a proof of concept that could lead to new drug design strategies.

Mayo Clinic Proceedings: Common blood disorder may not be linked to as many serious diseases
A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought.

New study suggests possible genetic links between environmental toxins and multiple myeloma
The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma.

Mayo researchers find race has role in incidence, survival of rare brain tumor
The incidence of a rare and deadly tumor called primary central nervous system lymphoma (PCNSL) is two times higher in black Americans, ages 20 to 49, than in white Americans, according to a Mayo Clinic study published in the June issue of Journal of Neuro-Oncology.

Genetic factors implicated in survival gap for breast, ovarian or prostate cancer
A new finding reveals that African-American patients with breast, ovarian, and prostate cancer tend to die earlier than patients of other races with these cancers, even when they receive identical medical treatment and when socioeconomic factors are controlled for.

Individuals who apply pesticides are found to have double the risk of blood disorder
A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general population.

X-rays help predict permanent bone damage from bisphosphonates
Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates.
More Multiple Myeloma Current Events and Multiple Myeloma News Articles
Multiple Myeloma: The Plain English Handbook for Patients and Care Givers

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
by Robert, J Heller (Author)

A concise and helpful overview of the disease, including therapies, medications, problems, and lifestyle changes. Many helpful hints in an easy to understand format which avoids a lot of hard to understand terminology in favor of a more light-hearted approach. Includes reproducible forms and many references to other sources.

100 Questions and Answers About Myeloma (100 Questions & Answers about . . .)

100 Questions and Answers About Myeloma (100 Questions & Answers about . . .)
by Asad Bashey (Author), Rafat Abonour (Author)

Whether you are a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor s and patient s views, 100 Questions & Answers About Myeloma gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a hematologist-oncologist specializing in myeloma treatment, and featuring insider advice from an actual patient, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.

Treatment of Multiple Myeloma and Related Disorders

Treatment of Multiple Myeloma and Related Disorders
by S. Vincent Rajkumar (Editor), Robert A. Kyle (Editor)

Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. This book is aimed at the practitioner who is looking to put these advances into clinical context. It will serve as an up-to-date resource for treatment of myeloma and related disorders. Chapters are written by international authorities and contain color photos, diagrams, and algorithms outlining preferred treatment strategies. Relevant scientific information is integrated throughout, but the...

Myeloma (The Biology of Cancer)

Myeloma (The Biology of Cancer)
by Jerome E., Ph.d. Tanner (Author)

Myeloma is a form of cancer that rises from white blood cells called B lymphocytes. The disease usually causes malignant cells to grow within bone marrow. These cells interfere with marrow function as well as the immune system. Risk for myeloma has been linked to old age, being overweight, and environmental factors such as radiation exposure. Myeloma draws upon the most current medical research to explain the biology of this form of cancer, how it is diagnosed, and how it is treated.

Beating Multiple Myeloma/Plasma Cell Neoplasm Together Sweatshirt Large White

Beating Multiple Myeloma/Plasma Cell Neoplasm Together Sweatshirt Large White
by Shop Zeus



Fight Against Multiple Myeloma/Plasma Cell Neoplasm Mug

Fight Against Multiple Myeloma/Plasma Cell Neoplasm Mug
by Design a Product LLC

Text on mug: Fight Against Multiple Myeloma/Plasma Cell Neoplasm
* Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface.
* If you have new ideas or need help selecting text for your custom coffee mugs please contact us.
* Size: 11 oz. capacity ceramic coffee mug.

Multiple Myeloma Medical Guide

Multiple Myeloma Medical Guide
by Qontro Medical Guides (Author)

The Multiple Myeloma Medical Guide is a publication which has been designed to better help readers understand Multiple Myeloma. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Multiple Myeloma. The Multiple Myeloma Medical Guide is highly recommended for those interested in understanding and learning more about Multiple Myeloma.

Multiple Myeloma Awareness Ribbon Mouse Pad

Multiple Myeloma Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Multiple Myeloma Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Multiple Myeloma Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Multiple Myeloma Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

Clearly Charming Burgundy Ribbon - Multiple Myeloma Awareness Italian Charm 18k Gold and Enamel by Casa D'Oro

Clearly Charming Burgundy Ribbon - Multiple Myeloma Awareness Italian Charm 18k Gold and Enamel by Casa D'Oro
by Clearly Charming

Show your support for those people who are affected and for a cure. This charm is made by Casa D'Oro with 18k gold and baked enamel. It will make a great addition to your Italian charm bracelet or a perfect personalized gift. Commemorate special occasions, capture memorable moments, or simply show support for those affected by creating your own original Italian charm bracelet. Add Clearly Charming premium quality interlocking modular Italian charm links to your Italian Charm Bracelet and create your own memory bracelet.

Myeloma Therapy:: Pursuing the Plasma Cell (Contemporary Hematology)

Myeloma Therapy:: Pursuing the Plasma Cell (Contemporary Hematology)
by Sagar Lonial (Editor)

Therapeutic options for patients with myeloma have radically changed over the past ten years. Beginning with the advances in therapy resulting from the use of high dose therapy and autologous bone marrow or stem cell transplant, we have more than doubled the median survival for patients as a whole, and have now a wealth of different biology based treatment approaches for our patients in all disease stages. The purpose of this book is to update the various treatment options for patients with myeloma, as well as to focus on the emerging and speculative aspects of myeloma therapy. This will require review of basic mechanisms of disease as well as further discussions on how these mechanisms can best be targeted. While there will be text covering most areas of myeloma therapy, the prime...

© 2009 BrightSurf.com